$-0.17
(Market cap
$248 Mln
Revenue (TTM)
$74 Mln
P/E Ratio
7.1
P/B Ratio
2.8
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
3.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.4
-
Face value
--
-
Shares outstanding
94,724,146
10 Years Aggregate
CFO
$-249.97 Mln
EBITDA
$-260.93 Mln
Net Profit
$-262.35 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Compugen - ADR
| 69.6 | 9.0 | -6.0 | 76.5 | 31.2 | -17.3 | -9.2 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Compugen - ADR
| 0.0 | 176.7 | -83.3 | -64.5 | 103.2 | 174.7 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Compugen - ADR
|
2.6 | 247.7 | 74.0 | 35.2 | 0.0 | 36.8 | 7.1 | 2.8 |
| 0.5 | 8.9 | 1.3 | -9.1 | -1,029.8 | -- | -- | 6.2 | |
| 4.1 | 4.5 | 0.0 | -13.4 | -- | -90.4 | -- | 0.3 | |
| 68.8 | 254.1 | 1.8 | -16.3 | 0.0 | -46.1 | -- | 5.2 | |
| 43.6 | 2,290.5 | 188.7 | -97.6 | -38.6 | -- | -- | 19.3 |
Shareholding Pattern
View DetailsAbout Compugen - ADR
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline... consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel. Read more
-
CEO, President & Director
Dr. Anat Cohen-Dayag Ph.D.
-
CEO, President & Director
Dr. Anat Cohen-Dayag Ph.D.
-
Headquarters
Holon
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Compugen - ADR
What is the current share price of Compugen Ltd - ADR Today?
The share price of Compugen Ltd - ADR is $2.60 (NASDAQ) as of 28-Aug-2026 13:33 EDT. Compugen Ltd - ADR has given a return of 31.16% in the last 3 years.
What is the current PB & PE ratio of Compugen Ltd - ADR?
The P/E ratio of Compugen Ltd - ADR is 7.07 times as on 21-Aug-2026.
The P/B ratio of Compugen Ltd - ADR is 2.84 times as on 21-Aug-2026, a 0 premium to its peers’ median range of 2.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
4.10 |
1.41 |
2024 |
-9.63 |
2.49 |
2023 |
-9.33 |
2.67 |
2022 |
-1.84 |
0.80 |
2021 |
-11.17 |
3.44 |
What is the 52 Week High and Low of Compugen Ltd - ADR?
The 52-week high and low of Compugen Ltd - ADR are Rs 3.24 and Rs 1.30 as of 29-Aug-2026.
What is the market cap of Compugen Ltd - ADR?
Compugen Ltd - ADR has a market capitalisation of $ 248 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Compugen Ltd - ADR?
Before investing in Compugen Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.